Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Questex Podcasts and Fierce Life Sciences. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Questex Podcasts and Fierce Life Sciences or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

What can we learn from 2024’s biotech IPOs?

15:06
 
Share
 

Manage episode 454134547 series 3386301
Content provided by Questex Podcasts and Fierce Life Sciences. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Questex Podcasts and Fierce Life Sciences or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

After a promising start to the year, the biotech IPO market picked up steam again late this summer, with notable offerings from companies like Upstream, Septerna and BioAge. But what does this mean for the sector? Is market enthusiasm truly returning, or are we just seeing a temporary rebound?

To unpack these questions and look ahead to 2025, Fierce Biotech’s James Waldron chatted with Adam Farlow, Global Chair of Baker McKenzie’s Capital Markets Practice Group.

To learn more about the topics in this episode:

See omnystudio.com/listener for privacy information.

  continue reading

100 episodes

Artwork
iconShare
 
Manage episode 454134547 series 3386301
Content provided by Questex Podcasts and Fierce Life Sciences. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Questex Podcasts and Fierce Life Sciences or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

After a promising start to the year, the biotech IPO market picked up steam again late this summer, with notable offerings from companies like Upstream, Septerna and BioAge. But what does this mean for the sector? Is market enthusiasm truly returning, or are we just seeing a temporary rebound?

To unpack these questions and look ahead to 2025, Fierce Biotech’s James Waldron chatted with Adam Farlow, Global Chair of Baker McKenzie’s Capital Markets Practice Group.

To learn more about the topics in this episode:

See omnystudio.com/listener for privacy information.

  continue reading

100 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play